Prospective observational study of azithromycin in patients with acute exacerbation of fibrosing interstitial pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1090220095

Enrollment

Registered

2012-08-01

Start date

2012-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute exacerbation of fibrosing interstitial pneumonia

Interventions

Intervention type:DRUG Name of intervention: Dose form / Japanese Medical Device Nomenclature:INJECTION Route of administration / Site of application:INTRAVENOUS DRIP Dose per administration:500 mg Do

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Clinically confirmed acute exacerbation of fibrosing interstitial pneumonia patients in japan based on the JRS diagnostic criteria for acute exacerbation of interstitial pneumonia 2) Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with malignancy 2) Patients who have allergy symptoms for macrolide 3) Patient with long QT syndrome or ventricular tachycardia 4) Patients who are not appropriate to participate to the trial.

Design outcomes

Primary

Measure	Time frame
60-day survival from admission	—

Secondary

Measure	Time frame
safety of intravenous azithromycin for patients with acute exacerbation of fibrotic interstitial pneumonia	—

Countries

Japan

Contacts

Public Contactkodai kawamura

Saiseikai kumamoto hospital

kodai-kawamura@saiseikaikumamoto.jp+81-96-351-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026